Albireo Pharma, Inc.

Good afternoon and welcome to the ArborAO Pharma First Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the call, please press star zero on your telephone keypad. Please note that this conference is being recorded. I would now turn the call over to your host, Aans Wisdom, Managing Director of LifeSci Advisors. Thank you. You may begin.

Thank you, Operator, and good afternoon, everyone. Thank you for joining today's call. This afternoon, Albareo issued a press release highlighting its recent business accomplishments and financial results for the first quarter ended March 31, 2022. This press release is accessible via the company's website at www.albareopharma.com. Before proceeding, we would like to note that management's comments today may include forward-looking statements regarding the company's plans and expectations. These statements are being made under the Private Securities Litigation Reform Act of 1995, and they are subject to various risks and uncertainties. Actual results may differ materially due to various important factors, including those described in the risk factors section of our most recent Form 10-K and subsequent SEC filings. These filings can be accessed from the investor section of our website at www.alboreofarma.com or on the SEC's website. Any forward-looking statements represent our views as of today, May 16, 2022, and should not be relied upon as representing our views as of any subsequent dates. We undertake no obligation to publicly update these statements. Now it is my pleasure to turn the call over to Ron Cooper, Albarrio's President and Chief Executive Officer. Ron?

Thank you, Hans, and thank you, everybody, for joining us. With me today are Simon Harford, our Chief Financial Officer, Pamela Stevenson, our Chief Commercial Officer, and Dr. Jan Motsen, Chief Scientific Officer and Head of R&D. Before we begin, please note that slides related to our key metrics and revenue for Build Bay uptake are available on our website if you wish to look at them during the call. While we're still early in the launch process, I am very pleased that today we reported another positive quarter with excellent execution on both the commercial and development fronts and we're continuing to build a strong business base. At this stage, we're on track with the BILVE launch, have delivered on all of our clinical development milestones, and are in a strong cash position, $216.7 million on our balance sheet. There are three important drivers of growth for Alvareo. One, the global launch of BILVE in PFIC. Two, expanding the use of BILVE in additional diseases through PFIC. phase three gold standard studies, algal syndrome, and biliary atresia. Three, the rapidly emerging early stage products in our pipeline for adult cholestatic and viral liver diseases. We are looking forward to a bright future with multiple milestone readouts. Now let me turn it over to Pamela to talk about the global launch of Bilve in PPIC. Pamela?